المؤلفون: Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, Yancey SW

المصدر: Journal of Asthma and Allergy, Vol Volume 14, Pp 675-683 (2021)

مصطلحات موضوعية: allergens and epitopes, eosinophils, asthma, asthma treatments, biologics, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: https://www.dovepress.com/response-to-mepolizumab-treatment-in-patients-with-severe-eosinophilic-peer-reviewed-fulltext-article-JAA; https://doaj.org/toc/1178-6965

URL الوصول: https://doaj.org/article/fb42034cd3754d6a9156168fe94d4ca6

المؤلفون: Müllerová H, Meeraus WH, Galkin DV, Albers FC, Landis SH

المصدر: International Journal of COPD, Vol Volume 14, Pp 741-755 (2019)

مصطلحات موضوعية: Acute exacerbations, burden of illness, eosinophils, multiple-inhaler triple therapy, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.dovepress.com/clinical-burden-of-illness-among-patients-with-severe-eosinophilic-cop-peer-reviewed-article-COPD; https://doaj.org/toc/1178-2005

URL الوصول: https://doaj.org/article/807a797d4e924bb188af86111f180b6e

المؤلفون: Howarth, P, Chupp, G, Nelsen, LM, Bradford, ES, Bratton, DJ, Smith, SG, Albers, FC, Brusselle, G, Bachert, C

المصدر: The Journal of allergy and clinical immunology. 145(6):1713

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:143938749

المؤلفون: Hartmann, CEA, Camejo, H Starkie, Gunsoy, NB, Mehta, RA, Albers, FC

المصدر: Thorax; 2017, Vol. 72 Issue: Supplement 3 pA90-A91, 2p

المؤلفون: Marwaha, H, Hartmann, CEA, Mehta, RA, Gunsoy, NB, Albers, FC

المصدر: Thorax; 2017, Vol. 72 Issue: Supplement 3 pA90-A90, 1p

المؤلفون: Chipps BE; Capital Allergy & Respiratory Disease Center, Sacramento, CA, United States., Papi A; Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy., Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand; Victoria University Wellington, Wellington, New Zealand., Israel E; Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA., Panettieri RA Jr; Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA., Albers FC; Avillion US Inc., Northbrook, IL, United States., Cooper M; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Darken P; Late Respiratory and Immunology Biometrics, AstraZeneca, Gaithersburg, MD, USA., Gilbert I; BioPharmaceuticals, US Medical, AstraZeneca, Wilmington, DE, United States., Trudo F; BioPharmaceuticals, US Medical, AstraZeneca, Wilmington, DE, United States., Weinberg M; Avillion US Inc., Northbrook, IL, United States., Cappelletti C; BioPharmaceuticals R&D, AstraZeneca, Durham, NC, United States. Electronic address: christycappelletti@att.net.

المصدر: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Jul 02. Date of Electronic Publication: 2024 Jul 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE

المؤلفون: Papi A; Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy., Chipps BE; The Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA., Beasley R; The Medical Research Institute of New Zealand; Capital and Coast District Health Board, and Victoria University of Wellington, Wellington, New Zealand., Panettieri RA Jr; Rutgers Institute for Translational Medicine and Science; Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA., Israel E; Brigham and Women's Hospital, Harvard Medical School, Boston, USA., Cooper M; BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK., Dunsire L; BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK., Jeynes-Ellis A; Avillion, London, UK., Rees R; Avillion, London, UK., Albers FC; Avillion, Northbrook, IL, USA., Cappelletti C; BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC, USA.

المصدر: Therapeutic advances in respiratory disease [Ther Adv Respir Dis] 2024 Jan-Dec; Vol. 18, pp. 17534666241232264.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 101316317 Publication Model: Print Cited Medium: Internet ISSN: 1753-4666 (Electronic) Linking ISSN: 17534658 NLM ISO Abbreviation: Ther Adv Respir Dis Subsets: MEDLINE

مواضيع طبية MeSH: Asthma*/drug therapy , Albuterol*/administration & dosage , Drug Combinations* , Bronchodilator Agents*/administration & dosage , Budesonide*/administration & dosage , Nebulizers and Vaporizers*, Humans ; Administration, Inhalation ; Adult ; Middle Aged ; Male ; Female ; Treatment Outcome ; Adolescent ; Young Adult ; Aged ; Anti-Asthmatic Agents/administration & dosage

المؤلفون: Chipps BE; Capital Allergy and Respiratory Disease Center, Sacramento, CA. Electronic address: bchipps@capitalallergy.com., Israel E; Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand., Panettieri RA Jr; Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ., Albers FC; Avillion US Inc., Northbrook, IL., Rees R; Avillion LLP, London, UK., Dunsire L; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Danilewicz A; Avillion LLP, London, UK., Johnsson E; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cappelletti C; BioPharmaceuticals R&D, AstraZeneca, Durham, NC., Papi A; Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

المصدر: Chest [Chest] 2023 Sep; Vol. 164 (3), pp. 585-595. Date of Electronic Publication: 2023 Mar 30.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0231335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-3543 (Electronic) Linking ISSN: 00123692 NLM ISO Abbreviation: Chest Subsets: MEDLINE

مواضيع طبية MeSH: Budesonide* , Asthma*/drug therapy , Asthma*/chemically induced, Humans ; Child ; Formoterol Fumarate ; Metered Dose Inhalers ; Administration, Inhalation ; Albuterol ; Double-Blind Method ; Bronchodilator Agents ; Treatment Outcome

المؤلفون: Papi A; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Chipps BE; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Beasley R; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Panettieri RA Jr; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Israel E; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Cooper M; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Dunsire L; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Jeynes-Ellis A; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Johnsson E; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Rees R; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Cappelletti C; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.)., Albers FC; From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington - all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women's Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) - both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.).

المصدر: The New England journal of medicine [N Engl J Med] 2022 Jun 02; Vol. 386 (22), pp. 2071-2083. Date of Electronic Publication: 2022 May 15.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Albuterol*/administration & dosage , Albuterol*/adverse effects , Albuterol*/therapeutic use , Asthma*/drug therapy , Budesonide*/administration & dosage , Budesonide*/adverse effects , Budesonide*/therapeutic use, Administration, Inhalation ; Adolescent ; Adult ; Child ; Child, Preschool ; Double-Blind Method ; Drug Combinations ; Ethanolamines/therapeutic use ; Formoterol Fumarate/therapeutic use ; Glucocorticoids/administration & dosage ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; Maintenance Chemotherapy ; Nebulizers and Vaporizers ; Symptom Flare Up ; Young Adult

المؤلفون: Albers FC; Respiratory Medical Franchise, GSK, Raleigh, North Carolina, USA., Bratton DJ; Clinical Statistics, GSK, Uxbridge, UK., Gunsoy NB; Value Evidence and Outcomes, GSK, Uxbridge, UK., Cockle SM; Value Evidence and Outcomes, GSK, Brentford, UK., Alfonso-Cristancho R; Value Evidence and Outcomes, GSK, Philadelphia, Pennsylvania, USA., Braunstahl GJ; Department of Pulmonary Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.

المصدر: The clinical respiratory journal [Clin Respir J] 2022 Mar; Vol. 16 (3), pp. 252-258. Date of Electronic Publication: 2022 Jan 26.

نوع المنشور: Journal Article; Meta-Analysis

بيانات الدورية: Publisher: Blackwell Publishing Country of Publication: England NLM ID: 101315570 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-699X (Electronic) Linking ISSN: 17526981 NLM ISO Abbreviation: Clin Respir J Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Asthmatic Agents*/therapeutic use , Asthma*/diagnosis, Antibodies, Monoclonal, Humanized/therapeutic use ; Double-Blind Method ; Humans ; Randomized Controlled Trials as Topic ; Severity of Illness Index ; Treatment Outcome